Maher B El Khatib, MD | |
738 Washington St Ste A, Attleboro, MA 02703-6948 | |
(508) 639-5321 | |
(508) 639-5241 |
Full Name | Maher B El Khatib |
---|---|
Gender | Male |
Speciality | Anesthesiology |
Experience | 29 Years |
Location | 738 Washington St Ste A, Attleboro, Massachusetts |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1194716829 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | 216854 (Massachusetts) | Secondary |
207L00000X | Anesthesiology | 216854 (Massachusetts) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Saint Anne's Hospital | Fall river, MA | Hospital |
Morton Hospital | Taunton, MA | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is | 6305749987 | 440 |
Excel Anesthesia Associates Pllc | 0042675282 | 23 |
Steward Medical Group Inc | 2860688728 | 1404 |
Orthopedics Rhode Island Inc | 7012225907 | 101 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Anaesthesia Associates Of Massachusetts, Pc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1568415289 PECOS PAC ID: 5193611267 Enrollment ID: O20040225000842 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Springfield Anesthesia Service Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1093768830 PECOS PAC ID: 0345228011 Enrollment ID: O20040709000365 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Steward Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000007 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Steward Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1629398219 PECOS PAC ID: 2860688728 Enrollment ID: O20101119000332 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Orthopedics Rhode Island Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1508241399 PECOS PAC ID: 7012225907 Enrollment ID: O20151021001533 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Associated Physicians Of Harvard Medical Faculty Physicians At Beth Is |
---|---|
Entity Type | Part B Supplier - Hospital Department(s) |
Entity Identifiers | NPI Number: 1245773308 PECOS PAC ID: 6305749987 Enrollment ID: O20170628003015 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Steward Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1043711914 PECOS PAC ID: 2860688728 Enrollment ID: O20180329001196 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Entity Name | Excel Anesthesia Associates Pllc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1639878713 PECOS PAC ID: 0042675282 Enrollment ID: O20230424000574 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Maher B El Khatib, MD 738 Washington St Ste A, Attleboro, MA 02703-6948 Ph: (508) 639-5321 | Maher B El Khatib, MD 738 Washington St Ste A, Attleboro, MA 02703-6948 Ph: (508) 639-5321 |
News Archive
InfraReDx, Inc., a medical device company providing intelligent cardiovascular diagnostic imaging technologies, today announced that its LipiScan™ IVUS Coronary Imaging System will be featured in several presentations during the annual Cardiovascular Research Technologies (CRT) 2011 meeting, being held February 27 through March 1, 2011 at the Omni Shoreham Hotel in Washington, D.C.
Telik, Inc. today announced the publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death; http://www.nature.com/cdd/journal/vaop/ncurrent/full/cdd201080a.html. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation.
The levels of an inflammatory chemokine were significantly elevated in patients with pancreatic cancer who were extremely obese, according to research conducted by scientists at the Jefferson Pancreatic, Biliary and Related Cancers Center. They presented their data at the 5th Annual Academic Surgical Congress, held in San Antonio.
Athletes with bone and cartilage knee damage who are treated with transplanted tissue can return to sports after surgery, according to a Hospital for Special Surgery study reported at the annual meeting of the American Orthopaedic Society for Sports Medicine, held July 15-18 in Providence, Rhode Island. The study (abstract 8970) overturns the widely held belief that patients who undergo this surgery do not return to athletics.
Findings from a federally funded study suggest that patients with locally advanced kidney cancer should not be treated with either adjuvant (post-surgery) sorafenib or sunitinib. The average period to disease recurrence was similar between those who received sorafenib or sunitinib after surgery (5.6 years) and those treated with placebo (5.7 years).
› Verified 4 days ago
Neelima Alluri, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-236-7430 | |
Shari Lurie, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Anesthesia Dept., Attleboro, MA 02703 Phone: 508-236-7430 | |
Uttara G Bhimani, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-236-7430 | |
Mark Lebovits, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Anesthesia Department, Attleboro, MA 02703 Phone: 508-236-7430 Fax: 508-236-7446 | |
Dr. Mohammed Bilal Chaudary, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-222-5200 | |
Do Chan, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Anesthesia Department, Attleboro, MA 02703 Phone: 508-236-7430 | |
Boris Shwartzman, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 211 Park St, Attleboro, MA 02703 Phone: 508-236-7430 |